Given that the limited number of patients and differences in biologic behavior pose challenges in conducting clinical trials in rare malignancies, researchers determined whether using genomic profiling for rare gynecologic malignancies is feasible and have clinical utility. They analyzed somatic variants in rare epithelial gynecologic cancer patients via an institutional molecular profiling program utilizing the Sequenom MassArray platform or the TruSeq Amplicon Cancer Panel on the MiSeq platform. They assessed clinical trial outcomes using RECIST 1.1, and time on treatment. They found that somatic molecular profiling was feasible and useful for detecting patients with rare gynecologic cancers who were candidates for genotype-matched clinical trials. Potential clinical activity have been demonstrated by genotype-matched trials, predominantly MEK-based combinations in KRAS and/or NRAS mutant Low Grade Serous ovarian cancer patients, as well as genotype-unmatched trials.
This article was published on MDLinx.